Bill Details
View committees (1)
View cosponsors (11)
- Rep. Babin, Brian [R-Texas-36]
- Rep. Moore, Riley M. [R-West Virginia-2]
- Rep. Ogles, Andrew [R-Tennessee-5]
- Rep. Webster, Daniel [R-Florida-11]
- Rep. Tenney, Claudia [R-New York-24]
- Rep. Harris, Andy [R-Maryland-1]
- Rep. Weber, Randy K. Sr. [R-Texas-14]
- Rep. Harris, Mark [R-North Carolina-8]
- Rep. Green, Mark E. [R-Tennessee-7]
- Rep. Brecheen, Josh [R-Oklahoma-2]
- Rep. McGuire, John J. [R-Virginia-5]
AI Summary This summary was generated by AI from the bill text. AI can get information wrong.
This bill would stop the Department of Health and Human Services, including the Food and Drug Administration, from treating pregnancy as a disease or illness when deciding whether to approve abortion drugs. It would also block the agency from using that idea to create or keep special safety rules for those drugs. In addition, the bill would cancel any existing abortion drug approvals that were made, even partly, on the theory that pregnancy is an illness. That would include the current approval of mifepristone.
- It tells HHS and the FDA not to treat pregnancy as an illness when reviewing abortion drugs.
- It would prevent the FDA from approving abortion drugs under the usual drug approval rules if that approval depends on calling pregnancy an illness.
- It would also stop the FDA from creating or continuing extra safety requirements for abortion drugs based on that idea.
- Any approval already in place that relied on treating pregnancy as an illness would be canceled, including the approval for mifepristone.
Official Summaries
Pregnancy Is Not an Illness Act of 2025
This bill prohibits the Food and Drug Administration (FDA) from treating pregnancy as an illness for the purposes of approving any abortion drug or imposing a risk evaluation and mitigation strategy for an abortion drug. The bill also nullifies FDA approval of any abortion drug that relied at all on the treatment of pregnancy as an illness, and specifically nullifies the FDA’s approval of the abortion drug mifepristone in effect before the bill is enacted.
Current Full Text
[Congressional Bills 119th Congress]
[From the U.S. Government Publishing Office]
[H.R. 795 Introduced in House (IH)]
<DOC>
119th CONGRESS
1st Session
H. R. 795
To prohibit the Department of Health and Human Services from treating
pregnancy as an illness for purposes of approving abortion drugs.
_______________________________________________________________________
IN THE HOUSE OF REPRESENTATIVES
January 28, 2025
Mrs. Miller of Illinois (for herself, Mr. Babin, Mr. Moore of West
Virginia, Mr. Ogles, Mr. Webster of Florida, Ms. Tenney, Mr. Harris of
Maryland, and Mr. Weber of Texas) introduced the following bill; which
was referred to the Committee on Energy and Commerce
_______________________________________________________________________
A BILL
To prohibit the Department of Health and Human Services from treating
pregnancy as an illness for purposes of approving abortion drugs.
Be it enacted by the Senate and House of Representatives of the
United States of America in Congress assembled,
SECTION 1. SHORT TITLE.
This Act may be cited as the ``Pregnancy Is Not an Illness Act of
2025''.
SEC. 2. PROHIBITION AGAINST TREATING PREGNANCY AS ILLNESS FOR PURPOSES
OF APPROVING ABORTION DRUGS.
(a) Prohibition.--The Department of Health and Human Services,
including the Food and Drug Administration, shall not treat pregnancy
as an illness for purposes of--
(1) approving any abortion drug under section 505 of the
Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355); or
(2) imposing or maintaining any risk evaluation and
mitigation strategy for an abortion drug under section 505-1 of
such Act (21 U.S.C. 355-1).
(b) Nullification of Approvals in Effect.--
(1) In general.--Any prohibited approval of an abortion
drug is hereby nullified.
(2) Prohibited approval defined.--In this subsection, the
term ``prohibited approval of an abortion drug''--
(A) means any approval of an abortion drug under
section 505 of the Federal Food, Drug, and Cosmetic Act
(21 U.S.C. 355) that relied in whole or in part on the
treatment of pregnancy as illness; and
(B) includes the approval of mifepristone in effect
under such section 505 on the day before the date of
enactment of this Act.
<all>